E. Picco

Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

S. Horton, M. Gianfrancesco, J. Yazdany, 2022, The Lancet Rheumatology.

Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: A multicenter Italian study.

M. Fabrini, R. Soffietti, M. Caroli, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence of musculoskeletal disorders and rheumatic diseases in an Argentinean indigenous Wichi community

I. Peláez-Ballestas, R. Quintana, A. Silvestre, 2020, Clinical Rheumatology.

The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders

L. Durelli, E. Versino, F. T. I. Group, 2008, Journal of Neurology.

Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

S. Horton, M. Gianfrancesco, J. Yazdany, 2021, The Lancet Rheumatology.

MRI activity and neutralising antibody as predictors of response to interferon β treatment in multiple sclerosis

L. Durelli, E. Versino, J. Killestein, 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

POS1188 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON OF DATA FROM THE ARGENTINE REGISTRY (SAR-COVID), WITH THE LATIN AMERICAN AND GLOBAL REGISTRY (GLOBAL RHEUMATOLOGY ALLIANCE)

E. Soriano, G. Pons-Estel, M. Scolnik, 2021, Annals of the Rheumatic Diseases.

Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry

E. Soriano, B. Pons-Estel, G. Pons-Estel, 2022, Clinical Rheumatology.